Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals develops clinical-stage immunotherapy medicines built around rose bengal sodium, a synthetic small molecule in the halogenated xanthene family. News about PVCT centers on its PV-10 and PV-305 formulations, research publications, preclinical disease models, and clinical-program activity across oncology, dermatology, and ophthalmology.
Recurring updates also cover VisiRose, the company’s ocular-therapeutics subsidiary, and rose bengal photodynamic antimicrobial therapy for infectious keratitis and other eye infections. Additional company announcements address proof-of-concept work in wound healing, infectious disease, tissue repair, hematology, and vaccine-adjuvant research, along with annual-meeting and other public-company governance matters.
Provectus (OTCQB: PVCT) announced updated data from its Phase 1 trial targeting metastatic uveal melanoma (mUM) patients treated with the investigational immunocatalyst PV-10. Presented at the 20th Congress of the International Society of Ocular Oncology in June 2022, findings highlighted successful responses in patients receiving PV-10 injections. The study allows for multiple tumor injections per treatment cycle with assessments every three months. Provectus continues to develop various immunotherapy medicines, focusing on oncology and other disease areas.
Provectus (OTCQB: PVCT) announced on June 23, 2022, that shareholders approved a reverse stock split and an authorized share reduction during the 2022 Annual Meeting held on June 22. Other approved proposals include the election of directors and executive compensation. The Board aims to enhance shareholder value through these measures. Detailed voting results are available in Provectus' Form 8-K filed the same day. The company focuses on developing immunotherapy medicines for various diseases, particularly in oncology and dermatology.
Provectus (PVCT) announced promising results from its Phase 1 trial of PV-10 for metastatic uveal melanoma (mUM), presented at ASCO 2022. Notably, 29% of Stage IV M1a mUM patients achieved a metabolic complete response (mCR), with survival times ranging from 12.4 to over 48.8 months post-treatment. The trial utilized advanced imaging techniques like PET-CT, affirming their effectiveness in monitoring treatment response. The findings suggest that PV-10 combined with immune checkpoint blockade may enhance patient outcomes, emphasizing the need for early intervention in mUM.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed its patent application 16/204,832 for a combination of topical PH-10 and systemic therapies to treat inflammatory skin conditions, including psoriasis and atopic dermatitis. This marks Provectus’ first patent award in dermatology. The patent is co-assigned with Rockefeller University, with Dr. James Krueger as co-inventor. PH-10 is a clinical-stage immunotherapy treatment. The company focuses on developing halogenated xanthene-based therapies across various medical areas, including oncology and virology.
Provectus (OTCQB: PVCT) announced that data from its ongoing clinical trial of PV-10, an investigational cancer immunotherapy, will be presented at the ASCO 2022 annual meeting from June 3-7, 2022, in Chicago. The focus is on treating metastatic uveal melanoma (mUM) to the liver. Key details include:
- Abstract Title: Metabolic complete responses in mUM patients treated with PV-10
- Abstract Number: 9543
- Session Date: June 6, 2022, 1:15-4:15 PM CDT
This presentation highlights the potential of PV-10 in oncology.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed patent application 16/688,319, which covers the use of PV-10 for treating hematologic cancers. This marks Provectus' first patent award in hematology. In vivo studies showed that mice with acute lymphoblastic leukemia treated with oral PV-10 had increased survival rates compared to control groups. Innovate Calgary is a co-assignee for this patent, with a co-inventor from the University of Calgary.
KNOXVILLE, TN, April 19, 2022 – Provectus (OTCQB: PVCT) announced proposals for its 2022 Annual Meeting on June 22, including a reverse stock split ranging from 1-for-10 to 1-for-50 and a corresponding authorized share reduction. Approval for these measures is contingent upon the reverse stock split passing. Other items on the agenda include director elections, executive compensation approval, and ratification of the independent accounting firm. A definitive proxy statement will follow the preliminary filing pending SEC review.
Provectus announced the addition of Dr. Aru Narendran to its Scientific Advisory Board. Dr. Narendran, a professor at the University of Calgary, is recognized for his significant contributions to pediatric oncology. His collaboration with Provectus over the past five years has led to preclinical research on the drug rose bengal sodium (RBS), which shows promise in treating various cancers including neuroblastoma and acute leukemias. The partnership has also resulted in multiple patents and unique discoveries related to RBS. Provectus values Dr. Narendran's insights to enhance its drug development efforts.
Provectus (OTCQB: PVCT) announced preclinical research on its investigational cancer immunotherapy, PV-10, presented at the AACR annual meeting in New Orleans. The research, led by Dr. Aru Narendran, demonstrates PV-10's cytotoxic effects on high-risk solid tumor cell lines, including breast and colorectal cancers. Key findings reveal PV-10’s ability to modulate apoptosis and autophagy pathways, and inhibit cancer cell migration. PV-10 has been administered in over 450 patients and is under investigation for both local and systemic treatment of various cancers.
Provectus (OTCQB: PVCT) announced the successful development of a second halogenated xanthene (HX) molecule, enhancing its existing pipeline that includes the clinical-stage rose bengal sodium (RBS). The newly synthesized HX, with a complex molecular name, expands Provectus' proprietary intellectual property portfolio. The company adheres to Quality-by-Design (QbD) principles and cGMP guidelines for its products. Vice Chair Dominic Rodrigues expressed optimism about the potential of this new small molecule in drug development, aiming for it to become a viable drug candidate.